EXAGEN INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
EXAGEN INC. (XGN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $12.81 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- EXAGEN INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $15.65.
- EXAGEN INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2020-03-31 was $19.04.
- EXAGEN INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $9.73, a 40.89% decline from fiscal 2024.
- EXAGEN INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $16.46, a 2.49% decline from fiscal 2023.
- EXAGEN INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $16.88, a 22.94% increase from fiscal 2022.
- EXAGEN INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $13.73, a 20.08% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.81 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $9.73 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $9.73 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $8.79 10-Q · filed 2025-07-29 | |||
| 2025-03-31 | $15.65 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $16.46 10-K · filed 2025-03-11 | |||
| 2023-12-31 | $16.88 10-K · filed 2024-03-18 | |||
| 2022-12-31 | $13.73 10-K · filed 2023-03-20 | |||
| 2021-12-31 | $17.18 10-K · filed 2022-03-22 | |||
| 2020-12-31 | $29.02 10-K · filed 2021-03-16 | |||
| 2020-09-30 | $29.11 10-Q · filed 2020-11-10 | |||
| 2020-06-30 | $29.22 10-Q · filed 2020-07-28 | |||
| 2020-03-31 | $19.04 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $42.08 10-K · filed 2020-03-25 | |||
| 2019-09-30 | $37.20 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |